Patents by Inventor Adrian Zetner

Adrian Zetner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthetic hemagglutinin as universal vaccine against infection by type B influenza viruses (IBV)
    Patent number: 11413345
    Abstract: A synthetic hemagglutinin (sHA) which represents the highest degree of conservation in the HA sequences of all Influenza B viruses (IVB) based on comprehensive bioinformatics analyses was cloned into an adenoviral vector. The recombinant adenovirus carrying the sHA gene was then delivered intransallyintranasally into DAB/2 mice. The animals were challenged with 5xLD50 influenza B viruses. We have found that the synthetic HA vaccines afford 100% protection against lethal challenge whereas 50% mice died in the control group. Furthermore, no virus was found in the lung of the vaccinated group while significant lung viruses were found in all mice of the controlled group. Consistent with the survival data and virus titre, severe pneumonia was found in all mice of the control group while no pathologic observation was made in animals receiving the vaccines.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: August 16, 2022
    Assignee: Her Majestry the Queen in Right of Canada as Represented by the Minister of Health
    Inventors: Xuguang Li, Gary Van Domselaar, Adrian Zetner
  • Synthetic Hemagglutinin as Universal Vaccine Against Infection by Type B Influenza Viruses (IBV)
    Publication number: 20200306363
    Abstract: A synthetic hemagglutinin (sHA) which represents the highest degree of conservation in the HA sequences of all Influenza B viruses (IVB) based on comprehensive bioinformatics analyses was cloned into an adenoviral vector. The recombinant adenovirus carrying the sHA gene was then delivered intransallyintranasally into DAB/2 mice. The animals were challenged with 5xLD50 influenza B viruses. We have found that the synthetic HA vaccines afford 100% protection against lethal challenge whereas 50% mice died in the control group. Furthermore, no virus was found in the lung of the vaccinated group while significant lung viruses were found in all mice of the controlled group. Consistent with the survival data and virus titre, severe pneumonia was found in all mice of the control group while no pathologic observation was made in animals receiving the vaccines.
    Type: Application
    Filed: November 16, 2018
    Publication date: October 1, 2020
    Inventors: Xuguang Li, Gary Van Domselaar, Adrian Zetner